The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
All going swimmingly mate.
Exceeding all expectations, so I’m lead to believe from the company comms.
Guess what, on top of that, new data released next week to demonstrate exactly how the higher doses have positively impacted those poor unfortunate souls.
We know for starters the drug is safe and already showing early signs of efficacy which isn’t that common in ph1, or is it? You tell me.
Completely agree Timster.
Although we’ve been shafted in the fund raise nothing else has changed?
Who in their right mind would sell at a significant loss now?
Why invest in an AIM share in the first place if you don’t have the balls to see through a little red in the ole portfolio??